Kinetics of maternally-derived serogroup A, C, Y and W-specific meningococcal immunoglobulin G in Malian women and infants.

Autor: Findlow H; Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, UK. Electronic address: helenfindlow@hotmail.com., Tapia MD; Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA., Sow SO; Centre pour le Développement des Vaccins, Bamako, Mali., Haidara FC; Centre pour le Développement des Vaccins, Bamako, Mali., Coulibaly F; Centre pour le Développement des Vaccins, Bamako, Mali., Keita AM; Centre pour le Développement des Vaccins, Bamako, Mali., Diallo F; Centre pour le Développement des Vaccins, Bamako, Mali., Doumbia M; Centre pour le Développement des Vaccins, Bamako, Mali., Traore A; Centre pour le Développement des Vaccins, Bamako, Mali., Schluterman N; Department of Epidemiology, University of Maryland, Baltimore, MD, USA., Clark DA; Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, USA., Borrow R; Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, UK., Levine MM; Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD, USA.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2019 Apr 24; Vol. 37 (18), pp. 2477-2481. Date of Electronic Publication: 2019 Apr 02.
DOI: 10.1016/j.vaccine.2019.03.045
Abstrakt: A prospective, randomised, controlled observer-blind trial measuring the efficacy and immunogenicity of trivalent influenza vaccine (TIV) and the immunogenicity of quadrivalent meningococcal conjugate vaccine (MCV) in pregnant women and their infants up to 6 months of age was conducted in Mali. Here we reported the immunogenicity of MCV, which was used as a comparator vaccine to TIV, in this population. Third-trimester pregnant Malian women were randomized to receive TIV or MCV. Blood samples were collected from women prior to vaccination, 28 days post-vaccination, at delivery and 3 and 6 months post-delivery and from infants at birth and 3 and 6 months of age. Meningococcal-specific serogroup (Men) A, C, Y and W-specific antibodies were measured by enzyme linked immunosorbent assay in a randomly selected subset of 50 mother-infant pairs where the mother had received MCV. At birth, 94.0% (47/50) of infants had MenA specific IgG levels ≥ 2 µg/mL decreasing to 72.9% and 30.4% at 3 and 6 months of age. For MenC, 81.3% (39/48) of infants had MenC specific IgG levels ≥ 2 µg/mL at birth decreasing to 29.4% and 17.8% at 3 and 6 months of age. For MenY, 89.6% (43/48) of infants had MenY specific IgG levels ≥ 2 µg/mL at birth decreasing to 64.6% and 62.5% at 3 and 6 months of age. For MenW, 89.6% (43/48) of infants had MenW specific IgG levels ≥ 2 μg/ml at birth decreasing to 62.5% and 41.7% at 3 and 6 months of age. Maternal immunization with MCV conveyed protective levels of IgG at birth through to 3 months of age in the majority of infants.
(Crown Copyright © 2019. Published by Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: